Drug intelligence / Profile preview

lp11w

Development stage
Preclinical
Lead developer
Saint Louis University
Modality
Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration
Intratumoral
01

Overview

LP11W is an apoptogenic oncolytic adenovirus type 5 (HAdV5) vector developed for the treatment of solid tumors, specifically head and neck squamous cell carcinoma (HNSCC). The vector is genetically engineered to be defective in the expression of the E1B-19K protein, a viral homolog of the anti-apoptotic Bcl-2 protein that normally prevents premature host cell death during viral replication. By lacking E1B-19K, LP11W induces enhanced apoptotic and cytotoxic responses in infected tumor cells. Preclinical evaluation in immunocompetent Syrian hamster models has demonstrated that intratumoral administration of LP11W significantly suppresses the growth of both subcutaneous and orthotopic cheek pouch tumors. This anti-tumor activity is associated with increased caspase-3 activation and reduced tumor vascularity.

Other names
HAdV5-lp11wHAdV-5-lp11wHAdV 5-lp11wE1B-19K-defective adenovirusE-1B-19K-defective adenovirusE 1B-19K-defective adenovirusE1B-19K-mutant adenovirus type 5E-1B-19K-mutant adenovirus type 5E 1B-19K-mutant adenovirus type 5
02

Targets

BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)

Beyond the preview

Go deeper on lp11w.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lp11w.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call